This comprehensive report analyzes the global oral live attenuated rotavirus vaccine market, projecting significant growth through 2032. It examines key market drivers, including the urgent need to prevent severe diarrheal diseases in infants, while providing detailed segmentation by vaccine type, application, and geography. The study evaluates competitive landscapes, highlighting major players like Merck Sharp & Dohme and GSK. Furthermore, the analysis identifies emerging opportunities across the Americas, APAC, and Europe to support strategic decision-making.

Market Overview

The global Oral Live Attenuated Rotavirus Vaccine market is projected to experience significant growth from 2025 through 2032, expanding at a steady compound annual growth rate over the forecast period.

Disease Context and Vaccine Definition

• Rotavirus Impact: Rotavirus spreads easily among infants and young children. The virus can cause severe watery diarrhea, vomiting, fever, and abdominal pain. Children infected with rotavirus disease can become dehydrated and may require hospitalization.
• Vaccine Mechanism: A live attenuated rotavirus vaccine is created by reducing the virulence of a pathogen while maintaining its viability.
• Oral Administration: The oral rotavirus live attenuated vaccine refers to an oral vaccine containing attenuated rotavirus pathogens with weakened pathogenicity.

Regional Market Analysis

• United States: The market for Oral Live Attenuated Rotavirus Vaccine in the United States is estimated to increase from 2025 through 2032, growing at a consistent compound annual growth rate.
• China: The market for Oral Live Attenuated Rotavirus Vaccine in China is estimated to increase from 2025 through 2032, growing at a consistent compound annual growth rate.
• Europe: The market for Oral Live Attenuated Rotavirus Vaccine in Europe is estimated to increase from 2025 through 2032, growing at a consistent compound annual growth rate.

Market Segmentation

By Type

• Monovalent Vaccines
• Combination Vaccines

By Application

• Hospitals and Clinics
• Vaccination Sites

By Region

• Americas: United States, Canada, Mexico, Brazil
• APAC: China, Japan, Korea, Southeast Asia, India, Australia
• Europe: Germany, France, UK, Italy, Russia
• Middle East & Africa: Egypt, South Africa, Israel, Turkey, GCC Countries

Competitive Landscape

Key Players

The following companies have been profiled based on primary expert input and analysis of company coverage, product portfolio, and market penetration:

• Merck Sharp & Dohme
• GSK
• Bharat Biotech
• Lanzhou Biological Products Research Institute

Market Share and Dynamics

• Global key players include Merck Sharp & Dohme, GSK, Bharat Biotech, and Lanzhou Biological Products Research Institute.
• In 2025, the two largest global companies occupied a significant portion of the market share.

About the Report

Research Scope

LP Information, Inc. (LPI)'s newest research report, the “Oral Live Attenuated Rotavirus Vaccine Industry Forecast,” examines past sales and reviews total global Oral Live Attenuated Rotavirus Vaccine sales in 2025. It provides a comprehensive analysis by region and market sector of projected Oral Live Attenuated Rotavirus Vaccine sales for 2026 through 2032.

With sales broken down by region, market sector, and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral Live Attenuated Rotavirus Vaccine industry. The report offers a comprehensive overview, market shares, and growth opportunities by product type, application, key manufacturers, and key regions and countries.

Analytical Depth

This Insight Report provides a comprehensive analysis of the global landscape and highlights key trends related to:

• Product segmentation
• Company formation
• Revenue and market share
• Latest developments
• M&A activity

Furthermore, the report analyzes the strategies of leading global companies, focusing on:

• Oral Live Attenuated Rotavirus Vaccine portfolios and capabilities
• Market entry strategies
• Market positions
• Geographic footprints

Methodology and Forecast

The report evaluates key market trends, drivers, and affecting factors shaping the global outlook. It breaks down the forecast by Type, Application, geography, and market size to highlight emerging pockets of opportunity. Using a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study offers a highly nuanced view of the current state and future trajectory of the global market.

Key Questions Addressed

• What is the 10-year outlook for the global Oral Live Attenuated Rotavirus Vaccine market?
• What factors are driving Oral Live Attenuated Rotavirus Vaccine market growth, globally and by region?
• Which technologies are poised for the fastest growth by market and region?
• How do Oral Live Attenuated Rotavirus Vaccine market opportunities vary by end market size?
• How does Oral Live Attenuated Rotavirus Vaccine break out by Type and by Application?

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Oral Live Attenuated Rotavirus Vaccine Annual Sales 2021-2032

    • 2.1.2 World Current & Future Analysis for Oral Live Attenuated Rotavirus Vaccine by Geographic Region, 2021, 2025 & 2032

    • 2.1.3 World Current & Future Analysis for Oral Live Attenuated Rotavirus Vaccine by Country/Region, 2021, 2025 & 2032

  • 2.2 Oral Live Attenuated Rotavirus Vaccine Segment by Type

    • 2.2.1 Monovalent Vaccines

    • 2.2.2 Combination Vaccines

    • 2.2.3 Oral Live Attenuated Rotavirus Vaccine Sales by Type

      • 2.2.3.1 Global Oral Live Attenuated Rotavirus Vaccine Sales Market Share by Type (2021-2026)
      • 2.2.3.2 Global Oral Live Attenuated Rotavirus Vaccine Revenue and Market Share by Type (2021-2026)
      • 2.2.3.3 Global Oral Live Attenuated Rotavirus Vaccine Sale Price by Type (2021-2026)

  • 2.3 Oral Live Attenuated Rotavirus Vaccine Segment by Application

    • 2.3.1 Hospitals and Clinics

    • 2.3.2 Vaccination Sites

    • 2.3.3 Oral Live Attenuated Rotavirus Vaccine Sales by Application

      • 2.3.3.1 Global Oral Live Attenuated Rotavirus Vaccine Sale Market Share by Application (2021-2026)
      • 2.3.3.2 Global Oral Live Attenuated Rotavirus Vaccine Revenue and Market Share by Application (2021-2026)
      • 2.3.3.3 Global Oral Live Attenuated Rotavirus Vaccine Sale Price by Application (2021-2026)

• 3 Global by Company

  • 3.1 Global Oral Live Attenuated Rotavirus Vaccine Breakdown Data by Company

    • 3.1.1 Global Oral Live Attenuated Rotavirus Vaccine Annual Sales by Company (2021-2026)

    • 3.1.2 Global Oral Live Attenuated Rotavirus Vaccine Sales Market Share by Company (2021-2026)

  • 3.2 Global Oral Live Attenuated Rotavirus Vaccine Annual Revenue by Company (2021-2026)

    • 3.2.1 Global Oral Live Attenuated Rotavirus Vaccine Revenue by Company (2021-2026)

    • 3.2.2 Global Oral Live Attenuated Rotavirus Vaccine Revenue Market Share by Company (2021-2026)

  • 3.3 Global Oral Live Attenuated Rotavirus Vaccine Sale Price by Company

  • 3.4 Key Manufacturers Oral Live Attenuated Rotavirus Vaccine Producing Area Distribution, Sales Area, Product Type

    • 3.4.1 Key Manufacturers Oral Live Attenuated Rotavirus Vaccine Product Location Distribution

    • 3.4.2 Players Oral Live Attenuated Rotavirus Vaccine Products Offered

  • 3.5 Market Concentration Rate Analysis

    • 3.5.1 Competition Landscape Analysis

    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.6 New Products and Potential Entrants

  • 3.7 Market M&A Activity & Strategy

• 4 World Historic Review for Oral Live Attenuated Rotavirus Vaccine by Geographic Region

  • 4.1 World Historic Oral Live Attenuated Rotavirus Vaccine Market Size by Geographic Region (2021-2026)

    • 4.1.1 Global Oral Live Attenuated Rotavirus Vaccine Annual Sales by Geographic Region (2021-2026)

    • 4.1.2 Global Oral Live Attenuated Rotavirus Vaccine Annual Revenue by Geographic Region (2021-2026)

  • 4.2 World Historic Oral Live Attenuated Rotavirus Vaccine Market Size by Country/Region (2021-2026)

    • 4.2.1 Global Oral Live Attenuated Rotavirus Vaccine Annual Sales by Country/Region (2021-2026)

    • 4.2.2 Global Oral Live Attenuated Rotavirus Vaccine Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Oral Live Attenuated Rotavirus Vaccine Sales Growth

  • 4.4 APAC Oral Live Attenuated Rotavirus Vaccine Sales Growth

  • 4.5 Europe Oral Live Attenuated Rotavirus Vaccine Sales Growth

  • 4.6 Middle East & Africa Oral Live Attenuated Rotavirus Vaccine Sales Growth

• 5 Americas

  • 5.1 Americas Oral Live Attenuated Rotavirus Vaccine Sales by Country

    • 5.1.1 Americas Oral Live Attenuated Rotavirus Vaccine Sales by Country (2021-2026)

    • 5.1.2 Americas Oral Live Attenuated Rotavirus Vaccine Revenue by Country (2021-2026)

  • 5.2 Americas Oral Live Attenuated Rotavirus Vaccine Sales by Type (2021-2026)

  • 5.3 Americas Oral Live Attenuated Rotavirus Vaccine Sales by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Oral Live Attenuated Rotavirus Vaccine Sales by Region

    • 6.1.1 APAC Oral Live Attenuated Rotavirus Vaccine Sales by Region (2021-2026)

    • 6.1.2 APAC Oral Live Attenuated Rotavirus Vaccine Revenue by Region (2021-2026)

  • 6.2 APAC Oral Live Attenuated Rotavirus Vaccine Sales by Type (2021-2026)

  • 6.3 APAC Oral Live Attenuated Rotavirus Vaccine Sales by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

  • 6.10 China Taiwan

• 7 Europe

  • 7.1 Europe Oral Live Attenuated Rotavirus Vaccine by Country

    • 7.1.1 Europe Oral Live Attenuated Rotavirus Vaccine Sales by Country (2021-2026)

    • 7.1.2 Europe Oral Live Attenuated Rotavirus Vaccine Revenue by Country (2021-2026)

  • 7.2 Europe Oral Live Attenuated Rotavirus Vaccine Sales by Type (2021-2026)

  • 7.3 Europe Oral Live Attenuated Rotavirus Vaccine Sales by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Oral Live Attenuated Rotavirus Vaccine by Country

    • 8.1.1 Middle East & Africa Oral Live Attenuated Rotavirus Vaccine Sales by Country (2021-2026)

    • 8.1.2 Middle East & Africa Oral Live Attenuated Rotavirus Vaccine Revenue by Country (2021-2026)

  • 8.2 Middle East & Africa Oral Live Attenuated Rotavirus Vaccine Sales by Type (2021-2026)

  • 8.3 Middle East & Africa Oral Live Attenuated Rotavirus Vaccine Sales by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers

  • 10.2 Manufacturing Cost Structure Analysis of Oral Live Attenuated Rotavirus Vaccine

  • 10.3 Manufacturing Process Analysis of Oral Live Attenuated Rotavirus Vaccine

  • 10.4 Industry Chain Structure of Oral Live Attenuated Rotavirus Vaccine

• 11 Marketing, Distributors and Customer

  • 11.1 Sales Channel

    • 11.1.1 Direct Channels

    • 11.1.2 Indirect Channels

  • 11.2 Oral Live Attenuated Rotavirus Vaccine Distributors

  • 11.3 Oral Live Attenuated Rotavirus Vaccine Customer

• 12 World Forecast Review for Oral Live Attenuated Rotavirus Vaccine by Geographic Region

  • 12.1 Global Oral Live Attenuated Rotavirus Vaccine Market Size Forecast by Region

    • 12.1.1 Global Oral Live Attenuated Rotavirus Vaccine Forecast by Region (2027-2032)

    • 12.1.2 Global Oral Live Attenuated Rotavirus Vaccine Annual Revenue Forecast by Region (2027-2032)

  • 12.2 Americas Forecast by Country (2027-2032)

  • 12.3 APAC Forecast by Region (2027-2032)

  • 12.4 Europe Forecast by Country (2027-2032)

  • 12.5 Middle East & Africa Forecast by Country (2027-2032)

  • 12.6 Global Oral Live Attenuated Rotavirus Vaccine Forecast by Type (2027-2032)

  • 12.7 Global Oral Live Attenuated Rotavirus Vaccine Forecast by Application (2027-2032)

• 13 Key Players Analysis

  • 13.1 Merck Sharp & Dohme

    • 13.1.1 Merck Sharp & Dohme Company Information

    • 13.1.2 Merck Sharp & Dohme Oral Live Attenuated Rotavirus Vaccine Product Portfolios and Specifications

    • 13.1.3 Merck Sharp & Dohme Oral Live Attenuated Rotavirus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.1.4 Merck Sharp & Dohme Main Business Overview

    • 13.1.5 Merck Sharp & Dohme Latest Developments

  • 13.2 GSK

    • 13.2.1 GSK Company Information

    • 13.2.2 GSK Oral Live Attenuated Rotavirus Vaccine Product Portfolios and Specifications

    • 13.2.3 GSK Oral Live Attenuated Rotavirus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.2.4 GSK Main Business Overview

    • 13.2.5 GSK Latest Developments

  • 13.3 Bharat Biotech

    • 13.3.1 Bharat Biotech Company Information

    • 13.3.2 Bharat Biotech Oral Live Attenuated Rotavirus Vaccine Product Portfolios and Specifications

    • 13.3.3 Bharat Biotech Oral Live Attenuated Rotavirus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.3.4 Bharat Biotech Main Business Overview

    • 13.3.5 Bharat Biotech Latest Developments

  • 13.4 Lanzhou Biological Products Research Institute

    • 13.4.1 Lanzhou Biological Products Research Institute Company Information

    • 13.4.2 Lanzhou Biological Products Research Institute Oral Live Attenuated Rotavirus Vaccine Product Portfolios and Specifications

    • 13.4.3 Lanzhou Biological Products Research Institute Oral Live Attenuated Rotavirus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.4.4 Lanzhou Biological Products Research Institute Main Business Overview

    • 13.4.5 Lanzhou Biological Products Research Institute Latest Developments

• 14 Research Findings and Conclusion